Order Article Reprints

Mehl J, Akhoundova D, Bacher U, Jeker B, Rhyner Agocs G, Ruefer A, Soltermann S, Soekler M, Winkler A, Daskalakis M, et al. Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery. Cancers. 2024; 16(10):1854. https://doi.org/10.3390/cancers16101854

Mehl, Julian, Dilara Akhoundova, Ulrike Bacher, Barbara Jeker, Gaëlle Rhyner Agocs, Axel Ruefer, Susanne Soltermann, Martin Soekler, Annette Winkler, Michael Daskalakis, and et al. 2024. "Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery" Cancers 16, no. 10: 1854. https://doi.org/10.3390/cancers16101854

Mehl, J., Akhoundova, D., Bacher, U., Jeker, B., Rhyner Agocs, G., Ruefer, A., Soltermann, S., Soekler, M., Winkler, A., Daskalakis, M., & Pabst, T. (2024). Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery. Cancers, 16(10), 1854. https://doi.org/10.3390/cancers16101854